Semaglutide is the biologically active component and ingredient in Wegovy, Ozempic, and Rybelsus
Concerning different types of diabetes, the reported prevalence of DPN in patients with type 1 diabetes (T1D) is about 28.7% and in type 2 diabetes (T2D) the prevalence was notably higher at approximately 50.7% [4]
For example, in real-world settings, semaglutide users reported an average weight loss of about 8% after one year, compared to nearly 15% seen in clinical trials
Bioanalytical analysis using LC-MS n requires precise, accurate, and robust methods to confidently evaluate pharmacokinetics and toxicokinetics
All patients must discuss their complete medical history, current medications, personal risk factors, and individual concerns with qualified healthcare providers before starting GLP-1 therapy